On Monday, Edison International (NYSE:EIX)’s shares declined -0.40% to $57.72.
Edison International (EIX) declared a quarterly common stock dividend of $0.4175 per share, payable on July 31, 2015, to shareholders of record on June 30, 2015.
Additionally, the Board of Directors of Southern California Edison Company recently declared the following dividends:
- A quarterly dividend of $1.0325 per share on the Series A preference stock, payable on July 31, 2015, to shareholders of record on July 2, 2015.
- A semi-annual dividend of $31.25 per share on the Series E preference stock, payable on August 1, 2015, to shareholders of record on July 2, 2015.
Edison International, through its auxiliaries, generates and supplies electricity. The company generates electricity through hydroelectric, diesel, natural gas, nuclear, and photovoltaic sources. It supplies electricity primarily to commercial, residential, agricultural and other, industrial, and public authorities through transmission and distribution networks.
Apollo Education Group Inc (NASDAQ:APOL)’s shares gained 0.14% to $14.03.
Apollo Education Group, Inc. (APOL) stated financial results for the three and nine months ended May 31, 2015, with third quarter revenue of $681.5 million and diluted earnings per share of $0.44, or $0.53 not taking into account special items.
Third Quarter 2015 Results of Operations
Apollo Education Group (the “Company”) stated net revenue for the third quarter 2015 of $681.5 million, contrast to $793.6 million for the third quarter 2014. Third quarter 2015 University of Phoenix New Degreed Enrollment was 29,400 and Degreed Enrollment was 206,900, contrast to New Degreed Enrollment of 33,900 and Degreed Enrollment of 241,900 for the prior year third quarter. Operating income for the third quarter 2015 was $90.7 million, contrast to $116.3 million for the third quarter 2014. Income from ongoing operations attributable to Apollo Education Group for the third quarter 2015 was $48.1 million, or $0.44 per share, contrast to $68.1 million, or $0.61 per share for the prior year third quarter.
Not taking into account special items, operating income was $101.6 million for the third quarter 2015, contrast to $140.3 million for the third quarter 2014, and income from ongoing operations attributable to Apollo Education Group for the third quarter 2015 was $57.5 million, or $0.53 per share, contrast to $86.9 million, or $0.78 per share, for the third quarter 2014. Adjusted Operating Income was $132.2 million for the third quarter 2015 contrast to $178.1 million for the third quarter 2014. (Special items and Adjusted Operating Income for the respective periods are comprised of in the reconciliation of GAAP to non-GAAP financial information tables of this press release.)
Apollo Education Group, Inc. provides private education services. It offers online and on-campus undergraduate, graduate, professional development, and other non-degree educational programs and services primarily to working learners in the United States and internationally. The company operates in University of Phoenix, Apollo Global, and Other segments. It offers various degree programs in advanced studies, business, criminal justice and security, education, health sciences and nursing, humanities and sciences, information systems and technology, and social sciences.
At the end of Monday’s trade, Health Care REIT, Inc. (NYSE:HCN)‘s shares dipped -0.42% to $68.46.
Health Care REIT, Inc. (HCN) notified holders of its 3.00% Convertible Senior Notes due 2029 that they continue to be entitled to convert all or a portion of their Notes into cash and, if applicable, shares of the company’s common stock (the “Conversion Option”) through the close of business on September 30, 2015. The Notes remain convertible because the closing price of shares of the company’s common stock, for at least 20 trading days during the 30 successive trading-day period ending on June 30, 2015, was greater than 120% of the conversion price in effect on June 30, 2015.
To convert a certificated Note, a holder must (1) complete and sign a conversion notice, with appropriate signature guarantee, on the back of each Note, (2) surrender the Notes to The Bank of New York Mellon Trust Company, N.A., which is serving as the conversion agent, (3) furnish appropriate endorsements and transfer documents if required by the registrar or the conversion agent, (4) pay the amount of interest, if any, the holder must pay in accordance with the indenture, and (5) pay any tax or duty if required following the indenture. To convert interests in a global Note, the holder must comply with The Depository Trust Company’s (“DTC”) applicable conversion program procedures.
Upon conversion, the principal amount of the Notes will be paid in cash and the conversion value, if any, will be paid in shares of common stock based upon the volume-weighted average prices per share of the company’s common stock during the 20-trading day period following the satisfaction of the conversion procedures described above.
A holder may convert a portion of the Notes. The converted portion must be a principal amount of $1,000 or a multiple of $1,000.
Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The firm primarily invests in senior living and health care properties.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ended its Monday’s trading session with 3.42% gain, and closed at $199.11.
Alexion Pharmaceuticals, Inc. (ALXN) declared that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the Company’s New Drug Application (NDA) for the use of Strensiq® (asfotase alfa) as a treatment for patients in Japan with hypophosphatasia (HPP), a life-threatening, ultra-rare metabolic disorder. Strensiq, a bone-targeted enzyme replacement therapy, is the first therapy approved in Japan for the treatment of patients with HPP. Alexion anticipates that initial patients with HPP in Japan will start commercial treatment with Strensiq by late Q3 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
